Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) have received a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 […]
Specialty pharmaceutical company Knight Therapeutics Inc. (GUD.TO) announced Thursday it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc.
StockNews.com assumed coverage on shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) in a research note published on Wednesday morning. The firm issued a buy rating on the stock. Separately, Truist Financial boosted their target price on Amneal Pharmaceuticals from $6.00 to $7.00 and gave the stock a buy rating in a research note on […]
StockNews.com initiated coverage on shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) in a report published on Wednesday. The firm issued a buy rating on the stock. Separately, Truist Financial upped their target price on Amneal Pharmaceuticals from $6.00 to $7.00 and gave the company a buy rating in a research report on Wednesday, November […]
StockNews.com initiated coverage on shares of Amneal Pharmaceuticals (NASDAQ:AMRX – Free Report) in a research note issued to investors on Tuesday morning. The brokerage issued a buy rating on the stock. Separately, Truist Financial upped their price objective on shares of Amneal Pharmaceuticals from $6.00 to $7.00 and gave the company a buy rating in […]